Engineered immune cells take on autoimmune diseases in early trial

NCT ID NCT07095075

Recruiting now Disease control Sponsor: Nanjing Legend Biotech Co. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dose, and see how long the cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LUCAR-DKS1 NK cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new way to control severe autoimmune diseases that haven't responded to other treatments.
What could go wrong: This is a very early, small trial focused on safety, not effectiveness. The therapy may not work, and there are risks of serious side effects from the cells or the pre-treatment chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease granulomatosis with polyangiitis idiopathic inflammatory myopathy Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY AUTOIMMUNE DISEASES

Contacts and locations

Locations

Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210029, China
The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
RECRUITING

Hefei, Anhui, 230036, China
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITING

Wenzhou, Zhejiang, 325015, China
The Third The People's Hospital of BengBu
NOT_YET_RECRUITING

Bengbu, Anhui, 233000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.